Scientific and clinical research, much of it sponsored by the US government, has shown CBD’s potential as a treatment for a wide range of conditions, including arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, depression, antibiotic-resistant infections, epilepsy, and other neurological disorders.
CBD has demonstrable neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere. Further evidence suggests that CBD is safe even at high doses.
BIOAVAILABILITY OF CBD - bi·o·a·vail·a·bil·i·ty - noun: the proportion of a drug or other substance that enters the circulation when introduced into the body and so is able to have an active effect.
Bioavailability of CBD varies greatly depending on the method of administration. The averages for CBD bioavailability by method of administration are:
6% – 15% for oral CBD (swallowed and digested)
35% sublingual - absorbed directly through the mouth
40% for vaporized
up to - 62% for intranasal (applied through the nose)